Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

In one aspect, compositions are described herein. In some embodiments, a composition described herein comprises, consists of, or consists essentially of an MRI-active or MRI-sensitive polymer or oligomer formed from (i) a non-alkoxylated and non-alkenoxylated citric acid, citrate, or ester/amide of citric acid, and optionally an alkoxylated or alkenoxylated citric acid, citrate, or ester/amide of citric acid, (ii) a polyol/polyamine such as a diol/diamine, (iii) a monomer comprising an MRI contrast agent, and (iv) an amino acid monomer. The polymer or oligomer may be photoluminescent and MRI-sensitive. In another aspect, imaging methods utilizing the compositions described herein are described. In another aspect, scaffolds, grafts, and films comprising, consisting of, or consisting essentially of the compositions described herein are described.

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

Polarized nuclear imaging and spectroscopy systems and methods are disclosed. In some embodiments, nuclei of a radioactive substance are polarized such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. The radioactive substance is selected such that the degree of anisotropy is enhanced. A tracer is introduced into a living subject for delivery to a target area of interest in the subject. The tracer is delivered such that nuclear spin relaxation of the tracer is inhibited during transport of the tracer to the target area of interest. Gamma rays from the gamma ray emission are detected, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject. In some embodiments, a radioactive substance is delivered to a target area of interest in the subject and the nuclei of the radioactive substance are polarized following delivery of the radioactive substance to the target area of interest, such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. Gamma rays are detected from the gamma ray emission, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject.

Polarized nuclear imaging and spectroscopy systems and methods are disclosed. In some embodiments, nuclei of a radioactive substance are polarized such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. The radioactive substance is selected such that the degree of anisotropy is enhanced. A tracer is introduced into a living subject for delivery to a target area of interest in the subject. The tracer is delivered such that nuclear spin relaxation of the tracer is inhibited during transport of the tracer to the target area of interest. Gamma rays from the gamma ray emission are detected, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject. In some embodiments, a radioactive substance is delivered to a target area of interest in the subject and the nuclei of the radioactive substance are polarized following delivery of the radioactive substance to the target area of interest, such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. Gamma rays are detected from the gamma ray emission, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject.

The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.

A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle:

##STR00001##

in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

The present application relates to methods and compounds for enhancing contrast in magnetic resonance imaging. The methods comprise administering compounds of Formula I(a) or I(b) to a subject and obtaining a magnetic resonance image of the subject. The present application also relates to methods of preparing compounds of the Formula I(a) as well as intermediate compounds used in such a method of preparation. ##STR00001##

Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: YXZ, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided.

The present disclosure relates to texaphyrin compounds linked with an antitumor antibiotic such as an anthcyanine antitumor antibiotic such as doxorubicin and danurubicin. The texaphyrin and the antitumor antibiotic are joined together by a group which is cleavable in vivo and results in increased activity and deliverance of the cytotoxic compound to target cells. Also provided herein are pharmaceutical compositions and methods of use thereof.